PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “DERMATITIS, ATOPIC”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,765 records · Page 98Linked to original sources

Variability of enzyme markers during clinical regression of atopic dermatitis.

Skin surface enzyme activities were found to be significantly different in healthy and in skin with atopic dermatitis and, following appropriate treatment, a close correlation was observed between the clinical staging of the atopic dermatitis and the levels of the assayed marker enzymes. Samples were taken, by stripping with simple adhesive tapes, from a group of subjects on cure in a spa. The corneocytes were recovered from the first layers of the stratum corneum. Aqueous extracts of the strips were tested for their activity on chromophoric substrates which allow fluorescence spectrometry to be used to assay the trypsin-like, acid-phosphatase-like and phospholipase-A2-like activities. We show that the restoration of return to activities close to those of healthy subjects is related to the general condition of the patients, who showed a clearly improved SCORAD. Recovery of the trypsin-like activity and attenuation of the phospholipase-like activity, paralleled the regression of the dermatitis as assessed by a decrease in clinically evaluated parameters of xerosis and inflammation.

Acid Phosphatase↗

Pustular patch test reactions in atopic dermatitis.

Pustular patch test reactions to 5% nickel sulfate were regularly produced in patients with atopic dermatitis when patches were placed over areas of skin with (a) follicular papules, (b) erythema, (c) lichenification, and (d) minimal trauma. The pustular patch test reactions seldom occurred in the normal-appearing skin of these patients. However, if the skin was traumatized prior to the patch test, the reaction was produced in the normal-appearing skin of atopic as well as control individuals. No pustular reactions occurred in the follicular lesions of keratosis pilaris, supporting the view that follicular lesions of atopic dermatitis differ from keratosis pilaris. It is suggested that pustular patch test reactions are caused by primary irritation.

Adult↗

Sporadic dystrophic epidermolysis bullosa with concomitant atopic dermatitis.

We describe a patient with sporadic dystrophic epidermolysis bullosa associated with well-documented atopic dermatitis. We discuss this case in relation to a newly described clinical subtype of epidermolysis bullosa known as epidermolysis bullosa pruriginosa, a dystrophic variant associated with prominent pruritus. The relations of this case of sporadic dystrophic epidermolysis bullosa with other dominantly inherited forms of dystrophic epidermolysis bullosa such as the Pasini variant, the pretibial variant, and Bart's syndrome are also discussed. The role of atopic dermatitis in exacerbating dystrophic epidermolysis bullosa in this patient raises an important consideration in the care of this group of patients.

Adult↗

Effect and correlation of serum total IgE, eosinophil granule cationic proteins and sensitized allergens in atopic dermatitis patients with or without rhinitis.

To understand the relevance of serological parameters and eliciting allergens in the patients with atopic dermatitis (AD) and patients with atopic dermatitis in combination with rhinitis (ADR), we compared the serum total IgE, major basic protein (MBP) and eosinophil cationic protein (ECP) levels and identified the sensitized allergens in these two groups. The serum levels of total IgE, MBP and ECP were not significantly different in these two groups. Patients with ADR had a higher positive rate of aeroallergens including housedust, mite (D.F), mite (D.P) and cockroach than patients with AD. However, a high positive rate of seafood allergens (include crab, shellfish and shrimp) was observed in patients with AD. The serum IgE level correlated well with serum MBP level (r = 0.603, P = 0. 019) in patients with ADR. There was a strong correlation between serum MBP and ECP level (r = 0.773, P = 0.005) in patients with AD and in patients with ADR (r = 0.721, P = 0.008). We also found that numbers of sensitized allergens correlated well with total IgE in patients with AD (r = 0.760, P = 0.001) and in patients with ADR (r = 0.487, P = 0.004). These results suggested that the aeroallergens are the most important allergens causing and aggravating atopic diseases in Taiwan. Seafood may play an important role in the pathogenesis of AD. We suggest the measurement of serum total IgE combined with Multiple Allergens Simultaneous Test-Chemiluminescent Assays(AST-CLA) test could be helpful in the diagnosis of atopic diseases.

Adolescent↗

Soluble E-selectin as a marker of disease activity in atopic dermatitis.

BACKGROUND: Augmentation in the expression of adhesion molecules on endothelial cells can regulate leukocyte migration. These molecules are also shed into the circulation. The level of soluble adhesion molecules in the serum is known to reflect the degree of systemic inflammation, and this level can therefore be used as a marker of inflammation. OBJECTIVE: To elucidate whether soluble adhesion molecules can be used as the marker of disease severity in atopic dermatitis, we examined the levels of soluble E-selectin, soluble intercellular adhesion molecule-1, and soluble vascular cell adhesion molecule-1 and compared these levels with the patients' symptom scores and their total serum IgE levels. METHODS: Fifty-three patients with atopic dermatitis were studied. Soluble adhesion molecules were measured by ELISA. RESULTS: The level of soluble E-selectin was higher in patients with atopic dermatitis than in healthy control subjects (p < 0.01). Moreover, soluble E-selectin is correlated with disease severity (p < 0.01). Soluble E-selectin also reflected the changes in symptom scores. In contrast, there were no differences in soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 between the patients and control subjects. CONCLUSION: Soluble E-selectin is a good marker of disease severity and of its activity in atopic dermatitis.

Adult↗

[Immunomodulation in the treatment of atopic dermatitis].

In the submitted review the authors present information on possibilities of immunomodulating treatment of atopic dermatitis. Immunosuppressive treatment comprises systemic corticosteroid administration (possibly combined with cytostatic immunosuppressive preparations), cyclosporin A and phototherapy. Immunopotentiating treatment of AD makes use mainly of modulating preparations with the nature of physiological substances close to the immune system, substances obtained from natural biological sources (thymic hormones) or in recent years more frequently substances of recombinant origin (interferons, interleukins). The use of immunopotentiating drugs of chemical origin (synthetic substances) is used less frequently in AD. The use of intravenous immunoglobulin preparations for severe forms of atopic dermatitis is only just starting.

Adjuvants, Immunologic↗

Transgenic mice which overproduce Th2 cytokines develop spontaneous atopic dermatitis and asthma.

We have investigated the role of Th2 cytokines in the development of atopic diseases using transgenic mice carrying large genomic segments containing IL4, IL13 and IL5 genes and overexpressing these Th2 cytokines. In vitro stimulated, but not unstimulated, Th2 cells from the transgenic mice expressed high levels of IL4, IL13 and IL5 compared to those from non-transgenic mice. The transgenic mice developed spontaneous atopic dermatitis and airway inflammation against environmental allergens. The affected regions for atopic dermatitis covered the entire body including skin in the face, ear, eye-lid, neck, hind region and tail. Histological features showed thickened epidermis and dermis and infiltration of large numbers of inflammatory cells in the affected regions. The transgenic mice also showed airway inflammation characteristic of asthma, including infiltration of inflammatory cells and hypertrophy of airway epithelial cells. These mice also expressed high level of serum IgE, which is a hallmark of atopic diseases. In summary, this study provides additional evidence that Th2 cytokines play key roles in atopic diseases.

Air Pollutants↗

Comparison of serum specific IgE antibodies to staphylococcal enterotoxins between atopic children with and without atopic dermatitis.

BACKGROUND: The skin of patients with atopic dermatitis (AD) exhibits a striking susceptibility to colonization and infection by Staphylococcus aureus. The exotoxins secreted by S. aureus can act as superantigens and classic allergens, inducing the production of functionally relevant specific IgE antibodies. The aim of this study was to compare the levels and positive rates of serum staphylococcal enterotoxin A (SEA)- and staphylococcal enterotoxin B (SEB)-specific IgE between atopic children with and without AD. METHODS: Sixty children with AD, 55 children with respiratory allergy without AD, and 24 nonatopic healthy children were studied. The levels and positive rates of serum SEA- and SEB-specific IgE were compared among three groups. The correlation between the levels or positive rates of serum SEA/SEB-specific IgE and the severity of AD or the presence of previous skin infections was studied. RESULTS: The children with AD had significantly higher levels and positive rates of serum SEA- and SEB-specific IgE than the atopic children without AD (P < 0.001) and the nonatopic children (P < 0.001). There was no significant difference in the levels and positive rates of serum SEA- and SEB-specific IgE between the atopic children without AD and the nonatopic children. With or without adjustment for the potential confounding effect of total serum IgE levels, the levels and positive rates of serum SEA- and SEB-specific IgE were significantly correlated with severity of AD (P <0.005), but they were not significantly different between AD children with and without previous skin infections. CONCLUSIONS: SEA and SEB may contribute to chronic inflammation and exacerbation of AD through the IgE-mediated immune response.

Adolescent↗

Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study.

BACKGROUND: The effect of specific immunotherapy (SIT) on eczema in atopic dermatitis is not known. Therefore, a multi-centre, randomized dose-response trial, double-blind with respect to the efficacy of a biologically standardized depot house dust mite preparation was performed. METHODS: Eighty-nine adults with a chronic course of atopic dermatitis, SCORAD >or=40 and allergic sensitization to house dust mites [CAP-FEIA >or=3] were included, of whom 51 completed the study. Subcutaneous SIT with a house dust mite preparation (Dermatophagoides pteronyssinus/D. farinae) applying maintenance doses of 20, 2,000 and 20,000 SQ-U in weekly intervals for 1 year. The main outcome measures addressed the change of the SCORAD as average of the values after 9 and 12 months of SIT in comparison with the value at baseline. RESULTS: The SCORAD declined in the three dose groups in a dose-dependent manner (P = 0.0368, Jonckheere-Terpstra test) and was significantly lower in the two high-dose groups (2,000, 20,000 SQ-U) compared with the low-dose group of 20 SQ-U (P = 0.0379, U-test) after 1 year of SIT. The use of topical corticosteroids was significantly reduced with higher doses (P = 0.0007, Mantel-Haenszel chi-square test). CONCLUSIONS: Allergen-SIT for 1 year with a house dust mite preparation is able to improve the eczema in patients with atopic dermatitis who are sensitized to house dust mite allergens and reduces the need for topical corticosteroids. SIT may be valuable in the treatment of this chronic skin disease.

Adolescent↗

Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children.

BACKGROUND: Tacrolimus is a potent immunosuppressant used in organ transplant recipients; an ointment formulation is being developed as a therapeutic agent for atopic dermatitis. OBJECTIVE: Our purpose was to define the pharmacokinetics and evaluate tacrolimus 0.3% ointment as therapy for moderate to severe atopic dermatitis. METHODS: Thirty-nine patients, 5 to 75 years of age, received 14 applications over 8 days. Serial blood samples were collected on days 1 and 8, with predose samples collected on days 2 through 7. Overall response and signs/symptoms were rated daily on days 1 through 11. Incidence of adverse events and laboratory profile were determined. RESULTS: Mean area under the curve (0.9 to 42.5 ng x hr/ml) was highly variable and appeared to be related to size of application area. No systemic accumulation of tacrolimus was observed. Comparison to historical intravenous data indicates that absolute bioavailability of topical tacrolimus was less than 0.5%. Ninety-five percent of patients showed at least good improvement. All adverse events were transient. Burning was the most common application site adverse event and vasodilatation ("flushing/warmth") was the most common nonapplication site adverse event. No drug-related changes in laboratory profile were observed. CONCLUSION: The results of this study suggest that tacrolimus 0.3% ointment may be a safe and effective therapy for atopic dermatitis.

Administration, Cutaneous↗

Long-term application of extracorporeal photochemotherapy in severe atopic dermatitis.

BACKGROUND: Extracorporeal photochemotherapy (ECP) using UVA irradiation of enriched leukocytes in the presence of methoxsalen as a photoactivatable substrate has been employed for the treatment of several immunologically mediated disorders. OBJECTIVE: Our purpose was to determine the efficacy and safety of long-term ECP in the treatment of severe atopic dermatitis. METHODS: Fourteen patients with severe recalcitrant atopic dermatitis were treated with ECP in an open clinical trial at 2-week intervals. Disease activity was scored before each ECP cycle by means of a standardized protocol. RESULTS: A complete clinical remission was achieved in 4 patients (29%). Five patients (36%) experienced a substantial response with reduction of skin inflammation by at least 75%, whereas in one patient (7%) disease activity was reduced by more than 50%. Four patients were withdrawn from the study for unresponsiveness. No clinical signs of immunosuppression or other severe adverse events became evident. CONCLUSION: Long-term ECP may have significant beneficial effects on the course of atopic dermatitis and should therefore be considered as a treatment modality for patients suffering from severe and otherwise refractory atopic skin disease.

Adult↗

Cyclosporin A in atopic dermatitis: therapeutic response is dissociated from effects on allergic reactions.

Fourteen patients with severe chronic atopic dermatitis were treated with cyclosporin A (CyA, Sandimmun; 5 mg/kg/day) for 7-16 weeks. All showed a marked clinical improvement and half could omit topical corticosteroid treatment during therapy. Adverse effects were minor, but two patients relapsed despite continued treatment. In the others, the disease recurred soon after stopping CyA. Serum IgE levels and prick-test responses were unchanged by CyA. Immediate and late-phase cutaneous responses to intradermal house dust mite antigen (HDM) were significantly increased during treatment; but a delayed response, present at 24 and 48 h, was unaffected. Four of six patients challenged with HDM patch tests to tape-stripped skin during treatment showed eczematous reactions at 48 h. Thus, cyclosporin A has a powerful therapeutic effect in atopic dermatitis but does not reduce allergic responses to inhalant antigens.

Adolescent↗

[Cyclosporin A in atopic dermatitis: therapeutic effect and effect on allergic reactions are dissociated from each other].

Fourteen patients with severe chronic atopic dermatitis were treated with cyclosporin A (CyA, Sandimmun; 5 mg/kg/day) for 7-16 weeks. All showed a marked clinical improvement and half could omit topical corticosteroid treatment during therapy. Adverse effects were minor, but two patients relapsed despite continued treatment. In the others, the disease recurred soon after stopping CyA. Serum IgE levels and prick-test responses were unchanged by CyA. Immediate and late-phase cutaneous responses to intradermal house dust mite antigen (HDM) were significantly increased during treatment; but a delayed response, present at 24 and 48 h, was unaffected. Four of six patients challenged with HDM patch tests to tape-stripped skin during treatment showed eczematous reactions at 48 h. Thus, cyclosporin A has a powerful therapeutic effect in atopic dermatitis but does not reduce allergic responses to inhalant antigens.

Adolescent↗

[Comparison of balneophototherapy and UVA/B mono-phototherapy in patients with subacute atopic dermatitis].

In a controlled prospective study we compared the efficacy of combined salt water bath and UVA/B phototherapy to a UVA/B mono-phototherapy in patients with subacute atopic dermatitis (AD). The patients in the balneophototherapy group (n=16) were treated with baths containing 3-5% of the synthetic salt Psori-sal(trade mark), followed immediately by UVA/B irradiation, while the other treatment arm (n=12) received UVA/B phototherapy alone. After 20 treatments the balneophototherapy group showed a statistically significant (p</=0.0015) reduction of the SCORAD score from 69.5 before to 36.8 after therapy. No statistically significant reduction in the SCORAD score could be observed in the UVA/B phototherapy group (50.6 before to 44.3 after therapy). The cumulative UVB dose was significantly lower in the balneophototherapy group (0.9 J/cm2) as compared to the UVA/B monotherapy group (2.0 J/cm2). Balneophototherapy was well tolerated by patients with atopic dermatitis and no side effects were observed. We conclude that balneophototherapy expands the therapeutic options for patients with subacute atopic dermatitis.

Adult↗

Delayed type hypersensitivity in atopic dermatitis.

Three different aspects of delayed type hypersensitivity in atopic dermatitis (A.D.) were studied. (a) Intradermal testing demonstrated that positive reactions to bacterial vaccines were distinctly lower in patients with A.D. (b) Patch testing in patients with A.D. compared to tests in patients with anal eczema showed a striking difference in results concerning the substances to which positive reactions were found. (c) Patients with A.D. (n = 18), atopics without A.D. (n = 10), patients with contact dermatitis (n = 10), and normal controls (n = 10), were patch tested with various human dander (H.D.) fractions after stripping the stratum corneum with skin tape. Only patients with A.D. showed positive reactions, the maximum response being at 24-48 hours. There was no difference in reaction pattern between partially purified H.D. subfractions. Histopathological examination revealed an eczema-reaction. Patch testing within the same patient groups with purified house dust mite allergen P1 demonstrated similar results. Although this finding argues against a specific role of H.D. allergen in A.D. it may at least be concluded that H.D. preparations have the capacity to provoke immediate as well as delayed type skin reactions.

Adolescent↗